A multicenter retrospective study comparing immunotherapy (anti-PD-1 and anti-CTLA-4) versus chemotherapy (mostly dacarbazine) showed a longer median OS for patients affected by advanced MM who received ICIs (approximately 16 months) respect to those treated with chemotherapy (8.8 months) [19,93]. This evidence concerns the gene CTLA4 and Miyoshi myopathy.